After doing initial studies on an established SARS-CoV-2 target RNA dependent RNA polymerase (RdRp), we are departing from protease studies and focus on RdRp along with additional NSP targets. Namely, RdRp (NSP12), is responsible for the transcription of viral genes and ultimately replication of the viral genome. The studied active site binds RNA and was previously studied in the context of remdesivir, galidesivir, molnupiravir and several other small molecules. Further reading below:
- Structure of replicating SARS-CoV-2 polymerase
- Identification of novel SARS-CoV-2 RNA dependent RNA polymerase (RdRp) inhibitors: From in silico screening to experimentally validated inhibitory activity
- RNA dependent RNA polymerase (RdRp) as a drug target for SARS-CoV2
- Ribavirin, Remdesivir, Sofosbuvir, Galidesivir, and Tenofovir against SARS-CoV-2 RNA dependent RNA polymerase (RdRp): A molecular docking study
Figure 1: RdRp in white color along with RNA chain and N4-hydroxycytidine from Molnupiravir in the active site (red stick model).
With best wishes,
Natalia, Marko, ÄŒrtomir, hoarfrost.
Source